HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 05, May 2021 – The Innovative Technology: Enhancing Healthcare for All       » Projecting Changes in Winds and Sea Surface       » 3D Biomaterial for Stem Cell Therapy against Arthritis       » Mapping Changes in Cancer Burden in China       » Singapore Enhances its National Precision Medicine Programme       » Enhancing Healthcare Workforce Productivity and Optimization      
Vol 25, No. 02, February 2021   |   Issue PDF view/purchase
BIOBOARD
Breakthrough Discovery of New Therapeutic Targets Against Alzheimer’s Disease
Researchers at the Hong Kong University of Science and Technology (HKUST) have identified new therapeutic targets for Alzheimer's disease by studying the patients' brain with a newly-developed methodology; opening up potential for new Alzheimer’s Disease drug development.

Alzheimer’s Disease, the most common form of dementia, currently affects over 50 million individuals worldwide and is projected to afflict 150 million people by 2050. Its pathological hallmarks include the accumulation of extracellular amyloid-beta depositions and neurofibrillary tangles. Over time, ineffective clearance of these pathological hallmarks leads to cellular dysfunction in Alzheimer’s Disease, resulting in memory loss, communication problems, reduced physical abilities, and eventually death.

Although the pathological mechanisms of Alzheimer’s Disease have been studied for decades, the disease remains incurable. One reason is that conventional research approaches have limited capability to identify molecular targets for drug development. Molecular and pathological pathway analysis generally examines Alzheimer’s Disease patients' brain as a single unit, which usually underestimates the contributions of different brain cell types to Alzheimer’s Disease and any abnormalities in them. This is especially the case with less-common cell types such as microglia (the brain's resident immune cells) and neurovascular cells (specifically endothelial cells), which only account for less than 5 percent and 1 percent of the total brain cell population, respectively.

However, a team led by Professor Nancy Ip, Vice-President for Research and Development, Director of the State Key Laboratory of Molecular Neuroscience, and Morningside Professor of Life Science at HKUST, has more than circumvented this problem. The team was able to identify several new potential molecular targets in endothelial cells and microglia for Alzheimer’s Disease drug development.

The team examined the functions of specific cell types in the post-mortem brains of Alzheimer’s Disease patients, which is typically impossible with conventional approaches, by using cutting-edge, single-cell transcriptome analysis, which can be used to characterize of the molecular changes in single cells. This yielded a comprehensive profile of the cell-type-specific changes in the transcriptome in the brains of Alzheimer’s Disease patients. Subsequent analysis identified cell subtypes and pathological pathways associated with Alzheimer’s Disease, highlighting a specific subpopulation of endothelial cells found in the brains' blood vessels. Accordingly, the team discovered that increased a formation of new blood vessels from current ones and immune system activation in a subpopulation of endothelial cells are associated with the pathogenesis of Alzheimer’s Disease, suggesting a link between the malfunction of blood vessels and Alzheimer’s Disease. The researchers also identified novel targets for restoring neural homeostasis in Alzheimer’s Disease patients.

The team leveraged on their single-cell transcriptome analysis to study the mechanism by which the cytokine interleukin-33 (IL-33), an important protein for immune signalling, exerts beneficial actions, making it a possible Alzheimer’s Disease therapeutic intervention. The researchers found that IL-33 reduces Alzheimer’s Disease pathophysiology by stimulating the development of a specific subtype of microglia that helps clear amyloid-beta, a neurotoxic protein found in Alzheimer’s Disease brains. The research team is also the first to capture data on the mechanisms by which microglia transform into an amyloid-beta-consuming phagocytic state, which is a major cellular mechanism for the removal of pathogens.

“The complex and heterogeneous cell composition within the brain makes it difficult to study disease mechanisms. The advancement of single-cell technology has enabled us to identify specific cell subtypes and molecular targets, which is critical for developing new interventions for Alzheimer's disease,” said Professor Ip.

The team has recently published their work in the prestigious scientific journals Proceedings of the National Academy of Sciences (PNAS) and Cell Reports.

NEWS CRUNCH  
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
news CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
news Highlights from the E&L China 2020 Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy